Merck: FDA grants priority review for Vaxneuvance
(CercleFinance.com) - Merck today announced that the US FDA has agreed to give priority review to its supplemental Biologics License Application (sBLA) for Vaxneuvance to prevent invasive pneumococcal disease in children aged 6 weeks to 17 years.
Vaxneuvance has the potential to provide significant protection against invasive pneumococcal disease in children and infants by targeting pneumococcal strains, or serotypes, that contribute to a significant burden of disease, it said.
The FDA gives priority review to drugs and vaccines that, if approved, would significantly improve the safety or efficacy of the treatment or prevention of a serious disease.
Copyright (c) 2021 CercleFinance.com. All rights reserved.